Page last updated: 2024-12-08
oxazepam glucuronide
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
oxazepam glucuronide: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 160870 |
| CHEBI ID | 168654 |
| MeSH ID | M0086459 |
Synonyms (17)
| Synonym |
|---|
| beta-d-glucopyranosiduronic acid, 7-chloro-2,3-dihydro-2-oxo-5-phenyl-1h-1,4-benzodiazepin-3-yl |
| 6801-81-6 |
| (2s,3s,4s,5r,6s)-6-[(7-chloro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl)oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid |
| CHEBI:168654 |
| oxazepam glucuronide |
| unii-26ik2c76no |
| glucopyranosiduronic aid, 7-chloro-2,3-dihydro-2-oxo-5-phenyl-1h-1,4-benzodiazepin-3-yl, beta-d- |
| 26ik2c76no , |
| .beta.-d-glucopyranosiduronic acid, 7-chloro-2,3-dihydro-2-oxo-5-phenyl-1h-1,4-benzodiazepin-3-yl |
| (2s,3s,4s,5r,6s)-6-[(7-chloro-2-hydroxy-5-phenyl-3h-1,4-benzodiazepin-3-yl)oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid |
| (2s,3s,4s,5r,6s)-6-((z)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1h-benzo[e][1,4]diazepin-3-yloxy)-3,4,5-trihydroxytetrahydro-2h-pyran-2-carboxylic acid |
| Q27254098 |
| oxazepam glucuronide solution |
| DTXSID40951163 |
| 7-chloro-2-hydroxy-5-phenyl-3h-1,4-benzodiazepin-3-yl hexopyranosiduronic acid |
| 28472-99-3 |
| DTXSID701028080 |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " The AUC of oxazepam glucuronide significantly increased from 4771 +/- 227 ng ml-1 h to 8116 +/- 644 ng ml-1 h and its elimination half-life increased from 10." | ( The influence of diflunisal on the pharmacokinetics of oxazepam. de Schepper, PJ; Tjandramaga, TB; van Hecken, AM; Verbesselt, R, 1985) | 0.65 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " Absorption was almost complete, with a bioavailability of 92." | ( Bioavailability and pharmacokinetics of oxazepam. Andreasen, F; Andreasen, PB; Døssing, M; Loft, S; Olesen, KL; Sonne, J; Victor, M; Vollmer-Larsen, A, 1988) | 0.27 |
| " It was a prerequisite to establish the bioavailability of oxazepam prior to succeeding studies on the oral disposition of the drug." | ( Factors and conditions affecting the glucuronidation of oxazepam. Sonne, J, 1993) | 0.29 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| "Biological samples were collected from eight male subjects after ingestion of 15 or 30 mg oxazepam on separate dosing occasions with an interval of 7 days." | ( The concentration of oxazepam and oxazepam glucuronide in oral fluid, blood and serum after controlled administration of 15 and 30 mg oxazepam. de Gier, JJ; Dijkhuizen, A; Egberts, AC; Hofman, BJ; Lusthof, KJ; Smink, BE; Uges, DR, 2008) | 0.63 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| glucosiduronic acid | Any substance produced by linking glucuronic acid to another substance via a glycosidic bond. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (14)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (35.71) | 18.7374 |
| 1990's | 3 (21.43) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 3 (21.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 27.39
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (27.39) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (6.25%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 15 (93.75%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||